Hospital Concerns Over Drug Supplies Mount as Meningitis Outbreak Spreads
"As we all start peeling back the layers of this onion, it turns out this has been an issue that any number of people have been quite aware of for some time," says Vanderbilt University Medical Center's William Schaffner, MD, past president of the National Foundation for Infectious Diseases. "It's just that nothing's been done about it. And it's not because harmful contamination issues have not occurred. They have."
Lawmakers and regulators, for whatever reasons, haven't wanted to tackle it, he says. Maybe it has been considered a state's rights issue, or maybe these compounding companies were seen as too small, or their operations too benign to cause much damage.
But here we have a major problem: Deaths and illness and panic in 10 states where 13,000 people have been exposed. Only now do the headlines say lawmakers are starting to take notice.
A patchwork of regulations
This scandal has exposed huge regulatory loopholes—a patchwork of widely varying state regulations, combined with unclear definitions for when a compounding pharmacy becomes a "manufacturer"—that have allowed these suppliers to escape U.S. Food and Drug Administration oversight.
Manufacturers do have to register with and meet requirements of the FDA, but compounding pharmacies do not, leaving unclear what propels a mere compounding pharmacy to manufacturer status.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- MA an Insurance Proving Ground for Providers
- Interventional Radiology No Longer a Sub-Specialty
- Targeting Self-Insured Populations
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- States Without Medicaid Expansion Search for Alternatives
- mHealth Tackles Readmissions